Industry Briefs: July 2, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Industry Briefs: July 2, 2012
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.


Company News

Arena Pharmaceuticals and Eisai have received FDA approval for a new molecular entity, Belviq (lorcaserin hydrochloride), for treating chronic weight management. Read More

Astellas Pharma has received approval for a new molecular entity, Myrbetriq (mirabegron) extended-release, for treating adults with overactive bladder. Read More

Biogen Idec and Isis Pharmaceuticals have announced a global collaboration for an antisense program targeting myotonic dystrophy. Read More

Encap Drug Delivery has invested $2 million to expand its facilities, for equipment for product mixing and capsule-filling. Read More

GEA Pharma Systems has agreed to supply a continuous manufacturing line for solid-dose products to an undisclosed pharmaceutical company. Read More

Janssen-Cilag, a Johnson & Johnson subsidiary, has completed the acquisition of Corimmun, a privately held German-based drug-development company. Read More

Takeda Farmacêutica Brasil, a subsidiary of Takeda Pharmaceutical has completed its acquisition of Multilab. Read More

People News

Alnylam Pharmaceuticals has expanded its management team. The company has appointed Oved Amitay as vice-president, head of commercial; Akshay Vaishnaw as executive vice-president and chief medical officer; Jared Gollob as vice-president of clinical research; and Lubomir Nechev as vice-president of process sciences. Read More

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here